Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B16D1 in head and neck squamous cell carcinoma and solid tumors
NCT06469008Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Jul 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL-B16D1 in head and neck squamous cell carcinoma (HNSCC) and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
BL-B16D1
03
Conditions
head and neck squamous cell carcinoma (HNSCC)solid tumor
Beyond the preview
Go deeper on NCT06469008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06469008.